Treatment options are still limited as to date no causal treatment is available (efficacy of the novel antibodies is still questionable especially concerning the side effects). Therefore, today an AD diagnosis will not significantly change treatment in terms of survival but it can be important for caretakers/family and for symptomatic treatment by e.g. AChE inhibitors, etc. While diagnosis is still mainly done by monitoring of the patient´s behaviour, novel PET tracers may allow imaging of the histology. This neuroimaging can be done by amyloid- or tau-directed tracers. The connection between amyloid load and cognitive function of AD patients is still part of debate, but tau tracers have shown good correlation in my opinion.